Findings of Research Misconduct, 41702 [E9-19795]
Download as PDF
41702
Federal Register / Vol. 74, No. 158 / Tuesday, August 18, 2009 / Notices
administer Subtitle B, ‘‘Incentives for
the Use of Health Information
Technology,’’ sections 3011 through
3017, with the exception of 3012(c)(5),
the Financial Support subsection.
These authorities may be redelegated.
The delegations authorize the National
Coordinator to administer the Incentives
for the Use of Health Information
Technology as provided in Subtitle B.
I hereby affirm and ratify any actions
taken by the National Coordinator or by
any other officials of the Office of the
National Coordinator for Health
Information Technology, which, in
effect, involved the exercise of this
authority prior to the effective date of
this delegation.
This delegation is effective upon date
of signature.
Dated: August 7, 2009.
Kathleen Sebelius,
Secretary.
[FR Doc. E9–19709 Filed 8–17–09; 8:45 am]
BILLING CODE 4150–24–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the Office of Research Integrity (ORI)
and the Assistant Secretary for Health
have taken final action in the following
case:
Ryan M. Wolfort, M.D., Ph.D.,
Louisiana State University Health
Sciences Center—Shreveport : Based on
the report of an investigation conducted
by Louisiana State University Health
Sciences Center—Shreveport (LSUHSC–
S) and additional analysis conducted by
ORI in its oversight review, the U.S.
Public Health Service (PHS) found that
Dr. Ryan M. Wolfort, who was a House
Officer in the Department of Surgery,
and a former graduate student,
Department of Molecular and Cellular
Physiology, LSUHSC–S, engaged in
research misconduct in the reporting of
research supported by National Heart,
Lung, and Blood Institute (NHLBI),
National Institutes of Health (NIH),
grants R01 HL26441 and P01 HL55552.
Respondent’s research misconduct
related to his dissertation research as a
graduate student, which he undertook at
the same time that he also was serving
as a House Officer at LSUHSC–S. ORI
acknowledges Dr. Wolfort’s cooperation
with the LSUHSC–S misconduct
proceedings.
jlentini on DSKJ8SOYB1PROD with NOTICES
SUMMARY:
VerDate Nov<24>2008
16:30 Aug 17, 2009
Jkt 217001
PHS found that Dr. Wolfort engaged
in research misconduct by falsifying and
fabricating data reported in three
publications 1 and one manuscript 2 that
had been submitted for publication,
reviewed, and returned for revision.
Specifically, Dr. Wolfort falsified and
fabricated data reported in research
examining the contribution of immune
mechanisms to early oxidative stress
and endothelial dysfunction in mice
with induced dietary
hypercholesterolemia by:
1. Admittedly fabricating tabulations
and the associated statistical analyses of
RT–PCR data on Nox-2 mRNA
expression in the three publications and
the manuscript;
2. Falsifying data and the associated
statistical claims, specifically by (a)
Admittedly falsifying the measurements
of endothelial function by myographic
recordings of aortic ring dilation in
reaction to vasoactive substances in the
three papers and manuscript, (b)
admittedly falsifying the measurement
of cytokine by cytometric bead assay in
paper 3, and (c) falsifying the
measurement of superoxide production
by cytochrome c reduction in papers 1
and 2, for which the underlying
spreadsheet data the Respondent claims
were unintentionally misrepresented,
massaged, and improperly collated, but
for which Respondent acknowledges
that the raw data were missing for all
three papers, admittedly because he
intentionally erased files and discarded
notebooks.
Dr. Wolfort has entered into a
Voluntary Exclusion Agreement in
which he has voluntarily agreed, for a
period of two (2) years, beginning on
July 13, 2009:
1 Wolfort, R.M., Stokes, K.Y., & Granger, D.N.
‘‘CN4+ T lymphocytes mediate
hypercholesterolemia-induced endothelial
dysfunction via a NAD(P)H oxidase-dependent
mechanism.’’ Am J Physiol Heart Circ Physiol
294:H2619–H2626, 2008; hereafter referred to as
‘‘paper 1.’’ Identified for retraction.
Wolfort, R.M., Manriquez, R., Stokes, K.Y., &
Granger, D.N. ‘‘Platelet-derived RANTES mediates
hypercholesterolemia-induced superoxide
production and endothelial dysfunction.’’
Arterioscler. Thromb. Vasc. Biol. Vol. 28 (pages
unavailable), as Epub 2008, July 17; hereafter
referred to as ‘‘paper 2.’’ Identified for retraction.
Wolfort, R.M., Stokes, K.Y., & Granger, D.N.
‘‘Immune cell-mediated endothelial cell
dysfunction during hypercholesterolemia involves
interferon-g dependent signaling.’’ Am J Physiol
Heart Circ Physiol, as Epub 2008, September 5;
hereafter referred to as ‘‘paper 3.’’ Retracted in Am
J Physiol Heart Circ Physiol 295(5):H2219, 2008
November.
2 Manuscript submitted to the journal Free
Radicals in Biology and Medicine, by Ryan M.
Wolfort, Katherine C. Wood, Robert P. Hebbel, and
Neil Granger, ‘‘Mechanisms underlying the
vasomotor dysfunction in sickle transgenic mice,’’
Ms Number FRBM–D–08–00454; hereafter referred
to as the ‘‘FRBM’’ manuscript.
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
(1) To exclude himself from any
contracting or subcontracting with any
agency of the United States Government
and from eligibility or involvement in
nonprocurement programs of the United
States pursuant to HHS’ Implementation
(2 CFR part 276 et seq.) of OMB
Guidelines to Agencies on Government
wide Debarment and Suspension (2
CFR, part 180); and
(2) To exclude himself from serving in
any advisory capacity to PHS, including
but not limited to service on any PHS
advisory committee, board, and/or peer
review committee, or as a consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852. (240) 453–8800.
John Dahlberg,
Director, Division of Investigative Oversight,
Office of Research Integrity.
[FR Doc. E9–19795 Filed 8–17–09; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Notice of Interest Rate on Overdue
Debts
Section 30.18 of the Department of
Health and Human Services’ claims
collection regulations (45 CFR Part 30)
provides that the Secretary shall charge
an annual rate of interest as fixed by the
Secretary of the Treasury after taking
into consideration private consumer
rates of interest prevailing on the date
that HHS becomes entitled to recovery.
The rate generally cannot be lower than
the Department of Treasury’s current
value of funds rate or the applicable rate
determined from the ‘‘Schedule of
Certified Interest Rates with Range of
Maturities.’’ This rate may be revised
quarterly by the Secretary of the
Treasury and shall be published
quarterly by the Department of Health
and Human Services in the Federal
Register.
The Secretary of the Treasury has
certified a rate of 111⁄4% for the quarter
ended June 30, 2009. This interest rate
will remain in effect until such time as
the Secretary of the Treasury notifies
HHS of any change.
Dated: August 6, 2009.
Molly P. Dawson,
Director, Office of Financial Policy and
Reporting.
[FR Doc. E9–19707 Filed 8–17–09; 8:45 am]
BILLING CODE 4150–04–P
E:\FR\FM\18AUN1.SGM
18AUN1
Agencies
[Federal Register Volume 74, Number 158 (Tuesday, August 18, 2009)]
[Notices]
[Page 41702]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-19795]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) and the Assistant Secretary for Health have taken final action in
the following case:
Ryan M. Wolfort, M.D., Ph.D., Louisiana State University Health
Sciences Center--Shreveport : Based on the report of an investigation
conducted by Louisiana State University Health Sciences Center--
Shreveport (LSUHSC-S) and additional analysis conducted by ORI in its
oversight review, the U.S. Public Health Service (PHS) found that Dr.
Ryan M. Wolfort, who was a House Officer in the Department of Surgery,
and a former graduate student, Department of Molecular and Cellular
Physiology, LSUHSC-S, engaged in research misconduct in the reporting
of research supported by National Heart, Lung, and Blood Institute
(NHLBI), National Institutes of Health (NIH), grants R01 HL26441 and
P01 HL55552.
Respondent's research misconduct related to his dissertation
research as a graduate student, which he undertook at the same time
that he also was serving as a House Officer at LSUHSC-S. ORI
acknowledges Dr. Wolfort's cooperation with the LSUHSC-S misconduct
proceedings.
PHS found that Dr. Wolfort engaged in research misconduct by
falsifying and fabricating data reported in three publications \1\ and
one manuscript \2\ that had been submitted for publication, reviewed,
and returned for revision. Specifically, Dr. Wolfort falsified and
fabricated data reported in research examining the contribution of
immune mechanisms to early oxidative stress and endothelial dysfunction
in mice with induced dietary hypercholesterolemia by:
---------------------------------------------------------------------------
\1\ Wolfort, R.M., Stokes, K.Y., & Granger, D.N. ``CN4+ T
lymphocytes mediate hypercholesterolemia-induced endothelial
dysfunction via a NAD(P)H oxidase-dependent mechanism.'' Am J
Physiol Heart Circ Physiol 294:H2619-H2626, 2008; hereafter referred
to as ``paper 1.'' Identified for retraction.
Wolfort, R.M., Manriquez, R., Stokes, K.Y., & Granger, D.N.
``Platelet-derived RANTES mediates hypercholesterolemia-induced
superoxide production and endothelial dysfunction.'' Arterioscler.
Thromb. Vasc. Biol. Vol. 28 (pages unavailable), as Epub 2008, July
17; hereafter referred to as ``paper 2.'' Identified for retraction.
Wolfort, R.M., Stokes, K.Y., & Granger, D.N. ``Immune cell-
mediated endothelial cell dysfunction during hypercholesterolemia
involves interferon-[gamma] dependent signaling.'' Am J Physiol
Heart Circ Physiol, as Epub 2008, September 5; hereafter referred to
as ``paper 3.'' Retracted in Am J Physiol Heart Circ Physiol
295(5):H2219, 2008 November.
\2\ Manuscript submitted to the journal Free Radicals in Biology
and Medicine, by Ryan M. Wolfort, Katherine C. Wood, Robert P.
Hebbel, and Neil Granger, ``Mechanisms underlying the vasomotor
dysfunction in sickle transgenic mice,'' Ms Number FRBM-D-08-00454;
hereafter referred to as the ``FRBM'' manuscript.
---------------------------------------------------------------------------
1. Admittedly fabricating tabulations and the associated
statistical analyses of RT-PCR data on Nox-2 mRNA expression in the
three publications and the manuscript;
2. Falsifying data and the associated statistical claims,
specifically by (a) Admittedly falsifying the measurements of
endothelial function by myographic recordings of aortic ring dilation
in reaction to vasoactive substances in the three papers and
manuscript, (b) admittedly falsifying the measurement of cytokine by
cytometric bead assay in paper 3, and (c) falsifying the measurement of
superoxide production by cytochrome c reduction in papers 1 and 2, for
which the underlying spreadsheet data the Respondent claims were
unintentionally misrepresented, massaged, and improperly collated, but
for which Respondent acknowledges that the raw data were missing for
all three papers, admittedly because he intentionally erased files and
discarded notebooks.
Dr. Wolfort has entered into a Voluntary Exclusion Agreement in
which he has voluntarily agreed, for a period of two (2) years,
beginning on July 13, 2009:
(1) To exclude himself from any contracting or subcontracting with
any agency of the United States Government and from eligibility or
involvement in nonprocurement programs of the United States pursuant to
HHS' Implementation (2 CFR part 276 et seq.) of OMB Guidelines to
Agencies on Government wide Debarment and Suspension (2 CFR, part 180);
and
(2) To exclude himself from serving in any advisory capacity to
PHS, including but not limited to service on any PHS advisory
committee, board, and/or peer review committee, or as a consultant.
FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852. (240) 453-8800.
John Dahlberg,
Director, Division of Investigative Oversight, Office of Research
Integrity.
[FR Doc. E9-19795 Filed 8-17-09; 8:45 am]
BILLING CODE 4150-31-P